RFK Jr.'s Sidestepping of the FDA on Peptides Access Sets a Scary Precedent

04.11.2026, 02:14 allure.com

In an unprecedented move, Health and Human Services (HHS) secretary Robert F. Kennedy, Jr, announced his plans to allow broader use of six previously restricted peptides—going against the advice of the Food & Drug Administration (FDA).

The six peptides in question—BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax—came up for discussion in July, when an advisory panel, the Pharmacy Compounding Advisory Committee (PCAC), voted in favor of loosening restrictions and moving the peptides to the 503A Bulks List, which means that compounding pharmacies could legally prepare them. Their advice was just that, advice. It did not mean the peptides were immediately added to the 503A Bulks List, nor that they were automatically FDA approved. But this latest development has moved the industry into “genuinely new territory,” says Dustin Robinson, a lawyer and founding partner of LumaLex Law, a firm that advises businesses in emerging health sectors (like peptides!).

The “interim enforcement discretion policy,” as it’s called, means compounding pharmacies can mix up the six peptides and the HHS won’t take enforcement action against them—as long as they follow a specific set of rules. Under these regulations, Robinson explains, pharmacies are protected only if they meet every condition, including: raw ingredients must come from FDA-registered manufacturers following good manufacturing practices; they must have a certificate of analysis (COA) that includes test results regarding identity, purity, endotoxins, and lack of contaminants like heavy metals; each product can only contain one peptide; each peptide is limited to specific forms, like intranasal use for Semax. The peptides cannot be purchased over the counter, either; they require a prescription from a licensed physician.

The document shared by the Department of Health and Human Services also calls out Kennedy in particular, who has been a vocal advocate for peptide use (although, not to state the obvious, is not a doctor or medical professional). “The Secretary of HHS has determined that this limited enforcement-discretion policy will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients,” it reads, adding that based on “available evidence” and the recommendations of a Pharmacy Compounding Advisory Committee, “the Secretary has determined that the policy advances patient choice and freedom while appropriately protecting patient safety.”

It’s worth reiterating that this policy comes without the blessing of the FDA. None of these peptides have undergone the notoriously rigorous and often time-consuming and expensive process to earn FDA approval, which means they don’t have the added safeguards and peace of mind that come with an FDA-approved substance. And when you’re injecting something into your body, you want it to be safe, right?

The Associated Press reports that FDA staff helped create the HHS’s safety guardrails, though the publication adds that the“Food and Drug Administration scientific staffers had little input on the decision and opposed the changes, according to six people familiar with its development.” In related news, Australian actor Richard Norton’s 2025 death was just linked to excess use of a peptide he got via a doctor’s prescription. (The peptide in question was not one of the six mentioned above.)

While it’s “tempting” to see this as a way to bypass the FDA, says David J. Holt, attorney and owner of Holt Law, a health-care business law firm in Minnesota and California, it’s “actually a highly specific safety valve” meant to “immediately rescue patients from a dangerous black market”—or that “for research only” loophole that allowed people to buy peptides from various sources without medical oversight. (By checking a box that says the peptides are “for research purposes only,” people can bypass the traditional pathways.)

These updates may actually put some much-needed rules and regulations in place, says Jay Campbell, co-founder of the American Peptide Association. The policy covers state-licensed pharmacies, federal facilities, and physicians compounding for a patient with a prescription, he explains. Pharmacies are also required to report any serious adverse events to the FDA and label the products as a compounded drug product that’s not for resale.

“Those are exactly the safeguards consumers have needed for years,” says Holt, adding that regulation aside, “this is a smart move to bring some manufacturing and related commerce in the peptide space back into the United States, as massive importing is currently occurring.”

According to Campbell, this decision sets two specific standards for the future. The first, he says, is political. “HHS has shown it will act on peptides even when the FDA’s career staff disagree, and that precedent will shape what happens to the next group [of peptides to be reviewed],” he shares.

The second standard is quality, as the interim policy “spells out exactly what testing a peptide should pass before it reaches a human being.” As Campbell explains, the raw ingredient must come from an FDA-registered manufacturer and requires the aforementioned COA “covering identity, purity, and endotoxins.” And because pharmacies will be required to report any adverse effects, that means more “real-world evidence” could be collected, says Campbell. “This should become the floor for every peptide sold in this country, not just the six in this policy,” he adds.

Don’t expect these changes to take place overnight, however, since pharmacies need to establish a compliant supply first, says Robinson. And don’t expect this to become par for the course for other experimental medications, adds Holt. “This happened because of a perfect storm: massive consumer demand, an existing PCAC advisory vote in favor of these peptides, a federal administration that appears pro-patient choice related to peptides, and finally a bureaucratic FDA rulemaking process that takes years to finalize,” he explains, calling it a “rare, targeted intervention” that helps protect patient safety and advancing patient choice. But again, “I'll reiterate this is not a green light for medical and wellness clinics to start compounding every peptide that pops up in their social media feed.”

Robinson expects we’ll see a similar approval process for the next batch of peptides, as the same panel from July is expected to weigh in on those in February. But regardless of what happens in the future, this policy isn’t permanent, he says. A future administration could “reverse it overnight.”

“Access should never be confused with scientific or clinical validation,” says Ava Shamban, MD, a board-certified dermatologist in California who has served as an investigator in FDA trials. From a scientific and clinical perspective, she says, it’s critical to distinguish between expanding access and establishing safety.

“This policy creates a potential pathway for greater access, but it does not necessarily establish a new standard for FDA drug approval,” she says. “That still requires rigorous evaluation of safety, efficacy, dosing, and manufacturing quality and further testing.”

To get a drug approved, explains Steve Kates, PhD, vice president of regulatory affairs at Dicerna Pharmaceuticals, not only do you have to show it’s efficacious, but you have to “justify a safety population.” For example, he says, Ozempic was tested on thousands of people before becoming widely available, creating a “massive amount” of safety data. The same safety data does not exist for these six peptides.

Efficacy, he adds, is determined by “clinically meaningful endpoints” the FDA can negotiate with, and that typically requires “two well-controlled clinical trials.” Though people may argue that the peptides have been used in trials, Dr. Kates says they are not “statistically significant.”

Dr. Shamban says that some peptides have been on the market for decades, “showing benefits and demonstrating efficacy in tens of thousands of patients anecdotally under a doctor's care, even if they aren't FDA-approved.” But that doesn’t mean they should be able to skip out on the evaluation process, nor does it mean they’re suddenly legal and approved.

Other peptides are “not even remotely close to the timing, usage, or testing levels that would allow them to be considered safe without the full rigor of FDA approval,” she adds. “The red flag is the precedent this could create if access substitutes for evidence. Innovation is essential in medicine, but regulatory flexibility should never diminish the scientific standards that protect patients.” Dr. Shamban notes that there’s still not a ton of “adequate human clinical data” to establish dosages, long-term safety, potential drug interactions, and whether the peptides consistently deliver the benefits they promise.

“Purity, sterility, consistency, and immune reactions are legitimate concerns, particularly with injectable compounds,” she explains. “And when we're discussing peptides marketed for collagen production, tissue repair, inflammation, or longevity, consumers need to understand that biological plausibility is not proof of clinical benefit.”

Robinson notes that these rules “cut out most of the overseas supply chain,” which means manufacturing capacity may be “tight” at first (peptide users, including people purchasing GLP-1 weight loss drugs, often turned to online resources and overseas suppliers to acquire their peptides). He also thinks this policy makes the argument for a gray market weaker. “For consumers, access runs through a prescription, which means telehealth will be the front door for most people.”

However, this new policy likely won’t stop the gray market business. Campbell expects prices to “climb substantially” due to the fact that demand will spike and pharmacies must now source their peptides from FDA-registered manufacturers and run the necessary quality testing, too.